Cell and gene therapies are revolutionizing the pharmaceutical landscape, offering unprecedented potential but also posing unique challenges to traditional drug distribution systems. Through its Biopartnering program, Bayer collaborates with innovators to enhance its portfolio of innovative solutions, secure access to cutting-edge technologies, and develop novel therapeutic products and solutions. The company’s Biotech team lends crucial support to innovators, aiding in the realization of their therapeutic projects. This includes not only addressing logistical needs in advance but also concentrating on the development and industrialization of their projects. To ensure the safe and efficient delivery of these innovative treatments, Bayer is actively adapting its cold chain and supply infrastructure. This adaptation encompasses the utilization of specialized temperature-controlled packaging, implementation of track and trace systems, and forming alliances with logistics service providers. Collaborating closely with every segment of the supply chain ecosystem is vital for the seamless and effective distribution